Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Tilray Brands Inc (TLRY) Price & Performance

Novavax IncTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Tilray Brands Inc — how do they compare? Novavax Inc trades at $7.95 (market cap $1.31B), while Tilray Brands Inc trades at $4.74 (market cap $649.42M). The key difference: Novavax Inc is far larger — about 2× Tilray Brands Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

NVAXTLRY
Market Cap
$1.31B$649.42M
Sector
HealthHealth
52-Week High
$11.19$21.00
52-Week Low
$6.22$3.88
Enterprise Value
$889.30M$816.55M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Tilray Brands Inc

TLRY trades at $4.77, up 7.92% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record fiscal 2026 revenue of $915 million (GlobeNewsWire, July 28, 2026) but posted a net loss. Key financials show a low P/S of 0.58 and P/B of 0.4, yet profitability remains challenged with negative net income margins and ROE.

Outlook is cautiously optimistic due to revenue growth and diversification into beverages and wellness, but high execution risk persists from consistent losses and competitive pressures. Analyst sentiment is mixed with 25% buy ratings, suggesting potential upside if profitability improves, though near-term volatility is likely.

Returns comparison

Trailing returns across standard periods

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY